AbbVie completes $21 billion buyout of Pharmacyclics

SHARE AbbVie completes $21 billion buyout of Pharmacyclics

AbbVie has completed its $21 billion buyout of Pharmacyclics.

The buyout adds another major revenue producer to Abbvie’s portfolio, which already includes the world’s top-selling drug, Humira. The deal gives the North Chicago-based drugmaker Imbruvica, a blood cancer treatment that Pharmacyclics makes and then markets with Johnson & Johnson’s Janssen Biotech.

Pharmacyclics Inc. will become a subsidiary of AbbVie and operate from its Sunnyvale, California, headquarters.

The buyout comes months after AbbVie Inc. scuttled a $55 billion deal to buy another drugmaker, Shire, after the U.S. government put in place new limitations on the tax benefits of reincorporating overseas. AbbVie would have reincorporated on the British island of Jersey, where Shire is incorporated.

The Latest
Josiah Brown, 3, was pronounced dead at 10:16 a.m. Sunday, the Cook County medical examiner’s office said. Victoria Moreno is charged with attempted murder.
This Bears win didn’t create much of a positive vibe.
Welcoming immigrants is a moral imperative of Christianity, Cardinal Blase Cupich told parishioners. Prayers were read in many languages, including Swahili, Italian and Vietnamese.
K.J. Osborn caught the go-ahead, 28-yard touchdown pass from Kirk Cousins with 45 seconds remaining.
Aaron Rodgers threw for 255 yards and two touchdowns.